UroGen Pharma (NASDAQ:URGN) Bolsa

UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHR

ATCH

ATPC

AVGR

CANG

CHCI

HCWC

LIDR

NMHI

PHIO

PIII

RGNX

RIME

SANG

STAF

URGN

YOSH

Las acciones de KB Home suben 9,1% tras superar expectativas de ganancias. Descubre los mayores ganadores y perdedores del mercado hoy.

Las acciones de KB Home se disparan un 9%; 20 acciones que se mueven en el premercado de EE.UU.

UroGen Pharma Ltd

WIIM

TARA

Protara Therapeutics shares are trading lower. The company announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002

Citigroup analyst Paul Lejuez maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and lowers the price target from $330 to $275.

Price Target

Analyst Ratings

LULU

Citigroup Maintains Neutral on Lululemon Athletica, Lowers Price Target to $275

Piper Sandler analyst Justin Crowley maintains Civista Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIVB#NASDAQ">CIVB</a>) with a Neutral and raises the price target from $23 to $24.

CIVB

Piper Sandler Maintains Neutral on Civista Bancshares, Raises Price Target to $24

Citigroup analyst Paul Lejuez maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Buy and lowers the price target from $215 to $150.

DECK

Citigroup Maintains Buy on Deckers Outdoor, Lowers Price Target to $150

Piper Sandler analyst Thomas Champion maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Overweight and lowers the price target from $90 to $80.

Piper Sandler Maintains Overweight on Zillow Gr, Lowers Price Target to $80

Piper Sandler analyst Thomas Champion maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Neutral and lowers the price target from $5120 to $5077.

BKNG

Piper Sandler Maintains Neutral on Booking Holdings, Lowers Price Target to $5077

ONON

On Holding shares are trading higher after Citigroup upgraded the stock from Neutral to Buy, while cutting its price target from $65 to $60.

Citigroup analyst Paul Lejuez maintains Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) with a Buy and lowers the price target from $36 to $30.

Citigroup Maintains Buy on Amer Sports, Lowers Price Target to $30

Piper Sandler analyst Thomas Champion maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and lowers the price target from $210 to $174.

EXPE

Piper Sandler Maintains Neutral on Expedia Group, Lowers Price Target to $174

Live On CNBC, Steve Weiss Announces Bought More UnitedHealth Group

Citigroup analyst Alicia Yap maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and lowers the price target from $56 to $51.

Citigroup Maintains Buy on JD.com, Lowers Price Target to $51

Piper Sandler analyst Thomas Champion maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and lowers the price target from $145 to $132.

ABNB

Piper Sandler Maintains Neutral on Airbnb, Lowers Price Target to $132

Piper Sandler analyst Crispin Love upgrades Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) from Neutral to Overweight and raises the price target from $12.5 to $14.

Upgrades

RITM

Piper Sandler Upgrades Rithm Capital to Overweight, Raises Price Target to $14

Piper Sandler analyst Paul Newsome upgrades Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) from Neutral to Overweight and lowers the price target from $384 to $378.

Piper Sandler Upgrades Aon to Overweight, Lowers Price Target to $378

Citigroup analyst Michael Rollins maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Buy and raises the price target from $425 to $445.

CHTR

Citigroup Maintains Buy on Charter Communications, Raises Price Target to $445

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Outperform and lowers the price target from $371 to $366.

Keefe, Bruyette & Woods Maintains Outperform on Willis Towers Watson, Lowers Price Target to $366

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="582" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster-1024x582.jpg" alt="" class="wp-image-11680" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster-1024x582.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster-300x171.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster-768x436.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">We&#8217;re In A Bear Market, And Stocks Have Further To Fall</h2>
That&#8217;s been our basic thesis since early this month. Big market participants (such as Bill Ackman) thought Trump&#8217;s tariffs were a negotiating tack or a bluff. Ergo, the extent of them wasn&#8217;t priced in, and when it was, we would go lower.&nbsp;
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/the-64-trillion-question"><img loading="lazy" decoding="async" width="922" height="861" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071148/64-Trillion.jpg" alt="" class="wp-image-11681" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071148/64-Trillion.jpg 922w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071148/64-Trillion-300x280.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071148/64-Trillion-768x717.jpg 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
Whether it makes sense to balance trade is a separate question. We think it does, as does Warren Buffett and as did the late Intel CEO, Andy Grove. But even if it&#8217;s a good policy, there is going to be a period of painful adjustment.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The warnings from public trucking companies, including LTL providers, tells us that the Trade War is about to take a massive toll on the economy. Most Americans are blissfully ignorant that Main Street activity has sharply down shifted.
&mdash; Craig Fuller &#x1f6e9;&#x1f69b;&#x1f682;&#x2693;&#xFE0F; (@FreightAlley) <a href="https://twitter.com/FreightAlley/status/1915970424648708338?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h2 class="wp-block-heading">Trading That Thesis&nbsp;</h2>
It&#8217;s a bearish thesis, so we&#8217;ve mainly focused on adding short exposure, with some exceptions. If something looks cheap&#8211;and likely to appreciate, we go long. And we do so on a day when the market is down. We did just that last Monday, placing long term, bullish bets on two Bitcoin-related names. 
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-bitcoin-bull"><img loading="lazy" decoding="async" width="920" height="842" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071408/Bitcoin-Bull.jpg" alt="" class="wp-image-11682" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071408/Bitcoin-Bull.jpg 920w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071408/Bitcoin-Bull-300x275.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071408/Bitcoin-Bull-768x703.jpg 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
We explained our logic there:&nbsp;
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><h2 class="wp-block-heading">Why Bitcoin?</h2>
Because Bitcoin is starting to behave like its own asset class, instead of like a more volatile version of the Nasdaq. While the NASDAQ 100-tracking Invesco QQQ Trust (QQQ) is down about 3% as I type this, Bitcoin is up about 2.5%.
<h2 class="wp-block-heading">Why These Two Stocks?</h2>
Because they are both profitable and cheap, with most of their market caps backed by cash and crypto:
<h3 class="wp-block-heading">Company A</h3>
<ul>
<li>Bitcoin Holdings: 742.1 BTC, valued at approximately $69.3 million</li>
<li>Ethereum Holdings: 27,623.9 ETH, valued at approximately $92.1 million</li>
<li>Cash and Cash Equivalents: Approximately $98.6 million</li>
<li>Total Market Capitalization: Approximately $325 million</li>
</ul>
Asset Composition Relative to Market Cap:
<ul>
<li>Bitcoin and Ethereum: ~50%</li>
<li>Cash: ~30%</li>
<li>Combined Liquidity (BTC + ETH + Cash): ~80%</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Company B</h3>
<ul>
<li>Bitcoin Holdings: 2,298 BTC, valued at approximately $214.6 million</li>
<li>Cash and Cash Equivalents: Approximately $8.9 million</li>
<li>Total Market Capitalization: Approximately $295 million</li>
</ul>
Asset Composition Relative to Market Cap:
<ul>
<li>Bitcoin: ~73%</li>
<li>Cash: ~3%</li>
<li>Combined (BTC + Cash): ~76%</li>
</ul>
</blockquote>
Company B was Semler Scientific, Inc. (SMLR), and it finished the week up more than 15%. 
<h2 class="wp-block-heading">Mostly Bearish Bets The Rest Of The Week</h2>
The rest of the week, we mainly added short exposure on market rallies. Specifically, we placed bets against:&nbsp;
<ul>
<li>High yield bonds, via the iShares iBoxx $ High Yield Corporate Bond ETF (HYG)</li>
<li>Trucking companies serving our ports.&nbsp;</li>
<li>Freight forwarders serving American small businesses importing from China.&nbsp;</li>
<li>Other vendors serving those small business.&nbsp;</li>
</ul>
We wrapped up the week with another bet against&nbsp;Nvidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) as it bounced above $110.&nbsp;
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-fading-the-rally-again"><img loading="lazy" decoding="async" width="922" height="815" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071815/Nvidia-Again.jpg" alt="" class="wp-image-11683" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071815/Nvidia-Again.jpg 922w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071815/Nvidia-Again-300x265.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071815/Nvidia-Again-768x679.jpg 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h2 class="wp-block-heading">Balancing Fear And Greed&nbsp;</h2>
We ended the week with three profitable exits, two on bearish trades (including an earlier bet against Nvidia), and one on a bullish put spread on&nbsp;Celestica, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>).&nbsp;
Options
<ol>
<li>Puts on Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). Bought for $1.81 on 4//14/2025; sold for $2.71 on 4/21/2025. Profit: 50%.</li>
<li>Put spread on Celestica (CLS 0.61%↑). Entered at a net credit of $3.12 on 3/27/2025; exited at a net debit of $2 on 4/25/2025. Profit: 59.6%.</li>
<li>Puts on Nvidia (NVDA -2.83%↓). Bought for $1.56 on 4/9/2025; sold for $4.02 on 4/21/2025. Profit: 158%.</li>
</ol>
Although we were bearish on Monday, we nevertheless decided to take profits on Apple and Nvidia again, as those options were expiring on Friday. In that case, our fear outweighed our greed, and enabled us to have three profitable exits this week instead of just one. We post our trade exits at the end of each week, including our losses. This week, we didn&#8217;t have any exits for losses, which was a welcome change from the previous week.&nbsp;
If you would like to trade alongside us next time, you can subscribe to our trading Substack/occasional email list below.&nbsp;
And if you just want to add some downside protection here,&nbsp;you can download the Portfolio Armor optimal hedging app by aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone). Our app can help you find the least expensive hedges given your risk tolerance and time frame.
<figure class="wp-block-image size-full"><a href="158%. Although we were bearish on Monday, we nevertheless decided to take profits on Apple and Nvidia again, as those options were expiring on Friday. In that case, our fear outweighed our greed, and enabled us to have three profitable exits this week instead of just one. We post our trade exits at the end of each week, including our losses. This week, we didn't have any exits for losses, which was a welcome change from the previous week. If you would like to trade alongside us next time, you can subscribe to our trading Substack/occasional email list below. And if you just want to add some downside protection here, you can download the Portfolio Armor optimal hedging app by aiming your iPhone camera at the QR code below (or by tapping here, if you're reading this on your phone). Our app can help you find the least expensive hedges given your risk tolerance and time frame."><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071945/QR-Code-3-3.jpg" alt="" class="wp-image-11684" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26072116/Widget-6.jpg" alt="" class="wp-image-11685" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26072116/Widget-6.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26072116/Widget-6-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Options

Opinion

AAPL

NVDA

Navigating A Roller Coaster Market

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains WSFS Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSFS#NASDAQ">WSFS</a>) with a Market Perform and lowers the price target from $66 to $64.

WSFS

Keefe, Bruyette & Woods Maintains Market Perform on WSFS Financial, Lowers Price Target to $64

ABBV

AbbVie shares are trading higher after multiple analysts raised their price targets on the stock. The company last week reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains USCB Financial Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USCB#NASDAQ">USCB</a>) with a Outperform and lowers the price target from $23 to $21.

USCB

Keefe, Bruyette & Woods Maintains Outperform on USCB Financial Holdings, Lowers Price Target to $21

Press Releases

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

HC Wainwright & Co.

D. Boral Capital

Goldman Sachs

Scotiabank

Ladenburg Thalmann

UroGen Pharma shares are trading higher after the company announced data from OPTIMA II Study of UGN-102, Newly Patient-Reported Outcomes from UGN-102 clinical trials. Also, the company highlighted an duration of response of nearly four years from a long-term follow-up study with JELMYTO.

Comments

UroGen Pharma

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL